abstract |
The present invention provides a salicylate analogue having the structure <IMAGE> wherein R is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl; pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, phenyl, naphthyl and cyclohexyl; wherein R1 is selected from the group consisting of hydrogen, a C1-C12 alkyl group, F, Cl, Br, I, CO2H, CONHR, CONR2, CO2R, C 3BOND N, CHO, COR, SO3, SO2NHR, SO2NR2, OH, OR, OCOR, SH, SR, OCONHR, OCONR2, SCOR, SCONHR, SCONR2 and NH2, NHR, NHCOR and NR2; and wherein R1 is in the 3-, 4-, 5- or 6-position, or a combination thereof. Also provided are various pharmaceutical compositions of the novel compounds of the present invention. |